Tag Archives: Vamil Divan

Credit Suisse Maintains Their Hold Rating on Bristol Myers (BMY)

In a report released today, Vamil Divan from Credit Suisse maintained a Hold rating on Bristol Myers (BMY – Research Report), with a price target of $59. The company’s shares opened today at $51.67. According to TipRanks.com, Divan is currently

Teva Pharma (TEVA) Receives a Hold from Credit Suisse

In a report released yesterday, Vamil Divan from Credit Suisse maintained a Hold rating on Teva Pharma (TEVA – Research Report), with a price target of $26. The company’s shares closed yesterday at $19.96. According to TipRanks.com, Divan has currently

Bristol Myers (BMY) Gets a Hold Rating from Credit Suisse

Credit Suisse analyst Vamil Divan maintained a Hold rating on Bristol Myers (BMY – Research Report) yesterday and set a price target of $59. The company’s shares closed on Friday at $49.89. According to TipRanks.com, Divan ‘s ranking currently consits

Merck & Company (MRK) Received its Third Buy in a Row

After Merrill Lynch and Barclays gave Merck & Company (NYSE: MRK) a Buy rating last month, the company received another Buy, this time from Credit Suisse. Analyst Vamil Divan maintained a Buy rating on Merck & Company yesterday and set

AbbVie (ABBV) Gets a Hold Rating from Credit Suisse

In a report released yesterday, Vamil Divan from Credit Suisse maintained a Hold rating on AbbVie (ABBV – Research Report), with a price target of $79. The company’s shares closed yesterday at $77.14, close to its 52-week low of $76.68.

AbbVie (ABBV) was Upgraded to a Hold Rating at Credit Suisse

In a report released yesterday, Vamil Divan from Credit Suisse upgraded AbbVie (ABBV – Research Report) to Hold, with a price target of $79. The company’s shares closed yesterday at $87.20. According to TipRanks.com, Divan is currently ranked with no